Similar articles

• Perilymphatic injections of cytokines: a new tool in active cancer immunotherapy. Experimental rationale and clinical findings.

  Forni G, Giovarelli M, Jemma C, Bosco MC, Caretto P, Modesti A, Santoni A, Forni M, Cortesina G, de Stefani A, et al. Forni G, et al. Ann Ist Super Sanita. 1990;26(3-4):397-409. Ann Ist Super Sanita. 1990. PMID: 2151108 Review.
• The tumor-cytokine transplantation assay and the antitumor activity of interleukin-4.

  Tepper RI. Tepper RI. Bone Marrow Transplant. 1992;9 Suppl 1:177-81. Bone Marrow Transplant. 1992. PMID: 1504664 Review. No abstract available.
• Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2.

  Pippin BA, Rosenstein M, Jacob WF, Chiang Y, Lotze MT. Pippin BA, et al. Cancer Gene Ther. 1994 Mar;1(1):35-42. Cancer Gene Ther. 1994. PMID: 7621236
• Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.

  Kim TS, Chung SW, Kim SH, Kang BY, Hwang SY, Lee JW. Kim TS, et al. Cancer Gene Ther. 2000 Jun;7(6):861-9. doi: 10.1038/sj.cgt.7700193. Cancer Gene Ther. 2000. PMID: 10880016
• Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.

  Toda M, Iizuka Y, Kawase T, Uyemura K, Kawakami Y. Toda M, et al. Cancer Gene Ther. 2002 Apr;9(4):356-64. doi: 10.1038/sj.cgt.7700446. Cancer Gene Ther. 2002. PMID: 11960286